KR20090071612A - 단백질 키나제 조정제로서의 바이시클릭 트리아졸 - Google Patents

단백질 키나제 조정제로서의 바이시클릭 트리아졸 Download PDF

Info

Publication number
KR20090071612A
KR20090071612A KR1020097008200A KR20097008200A KR20090071612A KR 20090071612 A KR20090071612 A KR 20090071612A KR 1020097008200 A KR1020097008200 A KR 1020097008200A KR 20097008200 A KR20097008200 A KR 20097008200A KR 20090071612 A KR20090071612 A KR 20090071612A
Authority
KR
South Korea
Prior art keywords
substituted
unsubstituted
alkyl
pyridinyl
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020097008200A
Other languages
English (en)
Korean (ko)
Inventor
피에르-이브 부노
크리스토퍼 로날드 스미스
엘리자베스 앤 제퍼슨
Original Assignee
에스지엑스 파마슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스지엑스 파마슈티컬스, 인코포레이티드 filed Critical 에스지엑스 파마슈티컬스, 인코포레이티드
Publication of KR20090071612A publication Critical patent/KR20090071612A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020097008200A 2006-10-23 2007-10-18 단백질 키나제 조정제로서의 바이시클릭 트리아졸 Abandoned KR20090071612A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US86255206P 2006-10-23 2006-10-23
US60/862,552 2006-10-23
US87030906P 2006-12-15 2006-12-15
US60/870,309 2006-12-15
US91376607P 2007-04-24 2007-04-24
US60/913,766 2007-04-24
US95284007P 2007-07-30 2007-07-30
US60/952,840 2007-07-30

Publications (1)

Publication Number Publication Date
KR20090071612A true KR20090071612A (ko) 2009-07-01

Family

ID=38956385

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097008200A Abandoned KR20090071612A (ko) 2006-10-23 2007-10-18 단백질 키나제 조정제로서의 바이시클릭 트리아졸

Country Status (25)

Country Link
US (1) US8507489B2 (https=)
EP (1) EP2084162B1 (https=)
JP (1) JP5378222B2 (https=)
KR (1) KR20090071612A (https=)
AR (1) AR063520A1 (https=)
AU (1) AU2007309149C1 (https=)
BR (1) BRPI0717320A2 (https=)
CA (1) CA2667428A1 (https=)
CO (1) CO6190620A2 (https=)
CR (1) CR10803A (https=)
DK (1) DK2084162T3 (https=)
EA (1) EA200970403A1 (https=)
ES (1) ES2393130T3 (https=)
IL (1) IL197958A0 (https=)
MA (1) MA30871B1 (https=)
MX (1) MX2009004059A (https=)
NO (1) NO20091618L (https=)
NZ (1) NZ575336A (https=)
PE (1) PE20080893A1 (https=)
PL (1) PL2084162T3 (https=)
PT (1) PT2084162E (https=)
SV (1) SV2009003235A (https=)
TN (1) TN2009000142A1 (https=)
TW (1) TW200835492A (https=)
WO (1) WO2008051808A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
EP2165710A1 (en) 2008-09-19 2010-03-24 Institut Curie Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
US8592448B2 (en) 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
CA2771432A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
EA030141B1 (ru) 2009-12-31 2018-06-29 Хатчисон Медифарма Лимитед Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
EP2569315A1 (en) 2010-05-14 2013-03-20 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
AR085183A1 (es) 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
UY33549A (es) * 2010-08-10 2012-01-31 Glaxo Group Ltd Quinolil aminas como agentes inhibidores de las quinasas
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
US8765760B2 (en) 2011-01-11 2014-07-01 Sunovion Pharmaceuticals, Inc. [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
CN103459396B (zh) * 2011-02-10 2015-08-19 诺瓦提斯公司 作为c-Met酪氨酸激酶抑制剂的[1,2,4]三唑并[4,3-b]哒嗪化合物
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー 融合二環キナーゼ阻害剤
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
CN103958509B (zh) * 2011-09-15 2015-12-23 诺华股份有限公司 作为酪氨酸激酶抑制剂的6-取代的3-(喹啉-6-基硫代)-[1,2,4]三唑并[4,3-a]吡啶化合物
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
JP2015512447A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害薬の組合せおよびその使用
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
WO2014089904A1 (en) 2012-12-10 2014-06-19 Abbvie Inc. Triazinone compounds
US9364405B2 (en) 2013-03-13 2016-06-14 Avon Products, Inc. Tyrosinase inhibitors
WO2014158943A1 (en) * 2013-03-13 2014-10-02 Avon Products, Inc Tyrosinase inhibitors
MX2015011438A (es) * 2013-03-13 2016-02-03 Hoffmann La Roche Procedimiento para preparar compuestos benzoxazepina.
US20150174034A1 (en) 2013-03-13 2015-06-25 Avon Products, Inc. Tyrosinase inhibitors
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
WO2014180182A1 (zh) * 2013-05-10 2014-11-13 江苏豪森药业股份有限公司 [1,2,4]三唑并[4,3-a]吡啶类衍生物，其制备方法或其在医药上的应用
WO2017049711A1 (zh) 2015-09-24 2017-03-30 上海海聚生物科技有限公司 喹啉类衍生物、其药物组合物、制备方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604091A (en) 1984-03-01 1997-02-18 Microgenics Corporation Methods for protein binding enzyme complementation
JPS60194443A (ja) * 1984-03-16 1985-10-02 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
JPS62228086A (ja) * 1985-12-23 1987-10-06 Takeda Chem Ind Ltd セフエム化合物
EP0228061A3 (en) 1985-12-23 1988-12-14 Takeda Chemical Industries, Ltd. Cephem compounds
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
WO2002083139A1 (en) * 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
US6960584B2 (en) * 2001-04-10 2005-11-01 Merck & Co., Inc. Inhibitors of Akt activity
US20030229453A1 (en) 2002-04-09 2003-12-11 Antonysamy Stephen Suresh Crystals and structures of PAK4KD kinase PAK4KD
WO2004058769A2 (en) * 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Triazolopyridazines as protein kinases inhibitors
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
CA2573573A1 (en) * 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
ES2355923T3 (es) 2004-08-26 2011-04-01 Pfizer, Inc. Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa.
MX2007007797A (es) 2004-12-27 2007-08-23 Alcon Inc Analogo de aminopirazina para tratar glaucoma y otras enfermedades mediadas por rho cinasa.

Also Published As

Publication number Publication date
DK2084162T3 (da) 2012-10-01
PL2084162T3 (pl) 2013-01-31
AU2007309149A1 (en) 2008-05-02
TW200835492A (en) 2008-09-01
EA200970403A1 (ru) 2009-10-30
WO2008051808A3 (en) 2008-07-24
PT2084162E (pt) 2012-10-09
SV2009003235A (es) 2009-10-15
PE20080893A1 (es) 2008-08-26
ES2393130T3 (es) 2012-12-18
NO20091618L (no) 2009-05-22
NZ575336A (en) 2012-04-27
IL197958A0 (en) 2009-12-24
AU2007309149B2 (en) 2012-09-06
AR063520A1 (es) 2009-01-28
WO2008051808A2 (en) 2008-05-02
MA30871B1 (fr) 2009-11-02
US8507489B2 (en) 2013-08-13
MX2009004059A (es) 2009-04-27
EP2084162B1 (en) 2012-09-12
CA2667428A1 (en) 2008-05-02
EP2084162A2 (en) 2009-08-05
CR10803A (es) 2009-06-16
JP2010507578A (ja) 2010-03-11
BRPI0717320A2 (pt) 2013-10-22
AU2007309149C1 (en) 2013-04-04
TN2009000142A1 (en) 2010-10-18
JP5378222B2 (ja) 2013-12-25
CO6190620A2 (es) 2010-08-19
US20090258855A1 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
KR101083177B1 (ko) 트리아졸로-피리다진 단백질 키나제 조정제
AU2007309149B2 (en) Bicyclic triazoles as protein kinase modulators
JP6785819B2 (ja) Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法
TWI494314B (zh) ５,７－取代的－咪唑并［１,２－ｃ］嘧啶
TWI503319B (zh) 吡啶酮和氮雜吡啶酮之化合物及其使用方法
CN101558070A (zh) 三唑并哒嗪蛋白激酶调节剂
TW202039489A (zh) Mat2a之雜雙環抑制劑及用於治療癌症之使用方法
WO2015038417A1 (en) Compounds for regulating fak and/or src pathways
CA2922230A1 (en) Biaryl acetamide compounds and methods of use thereof
KR20220085735A (ko) 아이소옥사졸리딘 유도체 화합물 및 이의 용도
CN113164481A (zh) 环烷-1,3-二胺衍生物
WO2024105363A1 (en) Pyridone and pyrimidinone inhibitors of hematopoietic progenitor kinase 1
CN103748095B (zh) 二环杂芳族化合物
HK40051544A (en) Tyrosine kinase inhibitors, compositions and methods there of

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20090422

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110316

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20111020

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee